Method for administering modulator targeting s1PR1 and s1PR4
NXC736, a selective S1P1 and S1P4 receptor binder, addresses the limitations of existing lymphocyte-suppressing treatments by safely and effectively reducing lymphocyte counts in lymphocyte-mediated diseases, offering a more sustained effect when administered twice daily in doses of 40 to 80 mg.
Patent Information
- Application Number
- PCT/KR2024/006583
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for lymphocyte-mediated diseases, such as alopecia areata and inflammatory bowel disease, face challenges in effectively suppressing lymphocyte counts without causing cardiovascular and respiratory side effects, as existing drugs like Fingolimod non-selectively bind to S1P receptors, leading to adverse effects.
The development of NXC736, a compound that selectively binds to S1P1 and S1P4 receptors, which is administered in a pharmaceutical composition in doses of 40 to 80 mg, either once or twice daily for at least 14 days, to suppress lymphocyte counts safely and effectively, formulated as capsules or tablets for oral administration.
NXC736 effectively reduces absolute lymphocyte counts by more than 50%, treating lymphocyte-mediated diseases like alopecia areata and inflammatory bowel disease, with a safer profile compared to existing drugs, and maintaining the decrease in lymphocyte count for a longer period when administered twice daily.
Smart Images

Figure KR2024006583_21112024_PF_FP_ABST
Abstract
Description
Methods of administering modulators targeting S1PR1 and S1PR4
[0001] The present invention relates to a method for administering a modulator targeting S1PR1 and S1PR4, and more particularly, to a method for administering a modulator targeting S1PR1 and S1PR4 that can effectively suppress the number of lymphocytes in the human body and effectively treat diseases mediated by lymphocytes.
[0002] NXC736 has a mechanism of action that binds to the sphingosine-1 phosphate (S1P) receptor, inducing a functional antagonist effect at the receptor, and exhibiting immunomodulatory and antifibrotic effects. In particular, NXC736 is a compound that selectively binds to S1P1 and S1P4, compared to Fingolimod, which non-selectively binds to S1P1, 3, 4, and 5 subtypes. Fingolimod, which was first approved as a functional antagonist acting on the S1P receptor, has had adverse effects on the cardiovascular and respiratory systems, particularly due to S1P3 binding, and the need for the development of drugs that selectively act on S1P has since emerged. Currently, a total of four substances, including Fingolimod, have received global product approval for indications of multiple sclerosis and ulcerative colitis, but NXC736 is the only substance that selectively binds to S1P1 and S1P4.
[0003] NXC736 has been demonstrated to be effective in treating various lymphocyte-mediated diseases, such as alopecia areata, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, and focal segmental glomerulosclerosis, through animal experiments (Korean Patent No. 10-2541577, Korean Patent No. 10-2541578, Korean Patent No. 10-2563719, Korean Patent No. 10-2541579).
[0004] However, these experiments only confirmed that a single dose of NXC736 was effective in treating various lymphocyte-mediated diseases in animals, and there was no disclosure or indication of an appropriate dosage or administration method that would show a therapeutic effect on lymphocyte-mediated diseases in humans.
[0005] Accordingly, there has been a need to establish a safer and more effective effective dosage and administration cycle for the treatment of diseases mediated by lymphocytes.
[0006] The present invention aims to provide a safe and effective dosage and administration cycle of a modulator targeting S1PR1 and S1PR4 in the prevention or treatment of lymphocyte-mediated diseases.
[0007] In order to achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating lymphocyte-mediated diseases, which comprises a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, wherein the active ingredient is administered to a subject in need thereof in a dose equivalent to 40 to 80 mg of the compound represented by Chemical Formula 1.
[0008] [Chemical Formula 1]
[0009]
[0010] Here,
[0011] R 1 is hydrogen;
[0012] R 2 is a hydrogen or acetyl group;
[0013] X is a single bond, C2 alkylene, or C2 alkenylene;
[0014] A is a five-membered heteroarylene ring containing three N atoms;
[0015] B is C 2-11 is a straight or branched chain alkylene;
[0016] C is a single bond or phenylene; and
[0017] D is hydrogen, phenyl and C 1-6 Selected from the group consisting of alkyl.
[0018] In the present invention, the compound represented by the chemical formula 1 may be characterized as being a compound represented by the chemical formula 2:
[0019] [Chemical Formula 2]
[0020]
[0021] In the present invention, the effective ingredient may be administered in a dosage of 50 to 70 mg.
[0022] In the present invention, it may be characterized in that the effective ingredient is administered in a dosage of 60 mg.
[0023] In the present invention, the pharmaceutical composition may be characterized in that it is administered once a day or twice a day.
[0024] In the present invention, the pharmaceutical composition may be characterized in that it is administered for at least 14 days.
[0025] In the present invention, the pharmaceutical composition may be characterized in that it is administered orally.
[0026] In the present invention, the pharmaceutical composition may be characterized by being formulated as a capsule or tablet suitable for oral administration.
[0027] In the present invention, the pharmaceutical composition may be characterized by further comprising a pharmaceutically acceptable carrier.
[0028] In the present invention, the pharmaceutical composition may be characterized by suppressing the absolute lymphocyte count to 50% or less compared to before administration.
[0029] In the present invention, the lymphocyte-mediated disease may be characterized as alopecia areata, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, or focal segmental glomerulosclerosis.
[0030] The present invention provides an optimal administration dose and cycle of a modulator (NXC736) targeting S1PR1 and S1PR4 that exhibits excellent safety when administered to humans and can suppress the absolute lymphocyte count by more than 50%, and can be effectively used to treat various diseases that are correlated with the absolute lymphocyte count, such as alopecia areata, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, and focal segmental glomerulosclerosis.
[0031] Figure 1 shows the mean NXC736 concentration-time profile after a single dose of NXC736.
[0032] Figure 2 shows the mean NXC736 concentration-time profile after repeated NXC736 administrations.
[0033] Figure 3 shows the PK parameters (C) of NXC736 after repeated administration of NXC736 by dose group. max,ss Wow AUC tau,ss ) is the result of comparison.
[0034] Figure 4 shows the mean percentage change in absolute lymphocyte count from the baseline time profile after a single dose of NXC736.
[0035] Figure 5 shows the mean percentage change in absolute lymphocyte count from the baseline time profile after repeated administration of NXC736.
[0036] Figure 6 shows the results of confirming the % change in absolute lymphocyte count over time compared to the initial absolute lymphocyte count (t=0) after a single (QD) administration of NXC736 at a dose of 20 mg / kg to healthy rats or two repeated (BID) administrations at a dose of 5 mg / kg or 10 mg / kg at 12-hour intervals.
[0037] Figure 7 shows the results of checking the area of alopecia areata lesions (AA lesion area) at two-week intervals after orally administering NXC736 twice daily (BID) for 12 weeks at a dose of 3 mg / kg or 10 mg / kg to alopecia areata model mice.
[0038] Figure 8 shows the pharmacodynamic parameters (Δ) of NXC736 after single or repeated administration of NXC736. max,ss ) is the result of comparison.
[0039] Figure 9 shows the average maximum percentage change in absolute lymphocyte count compared to baseline.
[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, the present application, including its definitions, will control. Unless the context otherwise requires, singular terms include plurals, and plural terms include the singular. All publications, patents, and other references mentioned herein are incorporated by reference in their entirety for all purposes, as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0041]
[0042] definition
[0043] As used herein, the term "about" is used to mean approximately, nearly, approximately, or to a degree. When the term "about" is used in conjunction with a numerical range, it modifies the range by extending the upper and lower bounds of the indicated values. Typically, the term "about" is used to modify the upper and lower bounds of the values stated herein by a 10 percent variation (upper or lower) above or below the stated values.
[0044] In all instances where aspects are described herein with the expression "comprising," it should be understood that other similar aspects described in terms of "consisting of" and / or "consisting essentially of" are also provided.
[0045] Additionally, in all cases described herein as embodiments in the form of a pharmaceutical composition, it should be understood that this is also provided in other similar forms described as pharmaceutical use forms, Swiss-type pharmaceutical use forms and / or therapeutic method forms for using the same.
[0046] As used herein, "effective dose" refers to the dosage and / or duration necessary to achieve the desired therapeutic outcome. The therapeutic outcome may include, for example, relief of symptoms or prolonged survival. The therapeutic outcome need not necessarily be a "cure."
[0047] As used herein, terms such as "treating," "treatment," "to treat," "palliating," or "to alleviate" refer to therapeutic measures that cure, delay, reduce symptoms, and / or halt the progression of a diagnosed pathological condition or disease. Accordingly, those in need of treatment include those who have already been diagnosed with a disease or are suspected of having a disease.
[0048] "Subject" or "individual" or "animal" or "patient" or "mammal" means any subject, particularly a mammalian subject, for which diagnosis, prognosis, or treatment is desired. Mammalian subjects include, but are not limited to, humans, livestock, farm animals, zoo animals, sport animals, pets, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, dairy cows; primates, such as apes, monkeys, orangutans, and chimpanzees; canids, such as dogs and wolves; felines, such as cats, lions, and tigers; equines, such as horses, donkeys, and zebras; bears, food animals, such as cattle, pigs, and sheep; ungulates, such as deer and giraffes; rodents, such as mice, rats, hamsters, and guinea pigs; and the like. In certain embodiments, the mammal is a human subject.
[0049] As used herein, a functional antagonist refers to a moiety that competitively binds to a receptor at the same site as an agonist (e.g., an endogenous ligand), but does not activate an intracellular response initiated by the active form of the receptor, thereby inhibiting the intracellular response induced by the agonist or partial agonist. An antagonist does not reduce the baseline intracellular response in the absence of the agonist or partial agonist.
[0050] As used herein, an agonist refers to a moiety that interacts with and activates a G-protein-coupled receptor, such as S1PR1 and S1PR4, thereby initiating a physiological or pharmacological response characteristic of the receptor. For example, an agonist may activate an intracellular response upon binding to the receptor, or enhance GTP binding to the membrane. In certain embodiments, the agonist of the invention is an S1PR1 and S1PR4 agonist that can facilitate sustained S1PR1 and S1PR4 internalization.
[0051]
[0052] therapeutic substance (active ingredient)
[0053] The present invention provides a compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as an active ingredient.
[0054] [Chemical Formula 1]
[0055]
[0056]
[0057] Here,
[0058] R 1 is hydrogen;
[0059] R 2 is a hydrogen or acetyl group;
[0060] X is a single bond, C2 alkylene, or C2 alkenylene;
[0061] A is a five-membered heteroarylene ring containing three N atoms;
[0062] B is C 2-11 is a straight or branched chain alkylene;
[0063] C is a single bond or phenylene; and
[0064] D is hydrogen, phenyl and C 1-6 Selected from the group consisting of alkyl.
[0065] The compound represented by the above chemical formula 1 may be any one compound selected from the following chemical group:
[0066] (1) 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol;
[0067] (2) 2-amino-2-(2-(1-octyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol;
[0068] (3) 2-amino-2-(2-(1-(4-hexylphenethyl)-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol;
[0069] (4) 2-amino-2-(1-dodecyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol;
[0070] (5) (E)-2-amino-2-(1-decyl-1H-1,2,3-triazol-4-yl)vinyl-1,3-diol;
[0071] (6) 2-amino-2-(2-(1-(8-phenyloctyl)-1H-1,2,3-triazolebutyl-4-yl)ethyl)propane-1,3-diol;
[0072] (7) N-(2-(1-dodecyl-1H-1,2,3-triazol-4-yl)-1,3-dihydrooxypropan-2-yl)acetamide;
[0073] (8) N-(4-(1-decyl-1H-1,2,3-triazol-4-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-yl)acetamide; and
[0074] (9) N-(4-(1-(4-hexylphenethyl)-1H-1,2,3-triazol-4-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-yl)acetamide.
[0075] The compound represented by the above chemical formula 1 may be a compound represented by the following chemical formula 2.
[0076] [Chemical Formula 2]
[0077]
[0078] In this specification, the compound represented by the above chemical formula 2 may be used interchangeably with the term 'NXC736'.
[0079] In this specification, any formulation in the examples containing the compound represented by the above chemical formula 2 as an active ingredient may be used in combination with a ‘clinical trial drug.’
[0080] The compounds according to the present invention may optionally be present as pharmaceutically acceptable salts, for example, pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids, for example, inorganic acids and organic acids. Representative acids include, but are not limited to, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, dichloroacetic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucinic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, oxalic acid, p-toluenesulfonic acid, and the like, for example, those pharmaceutically acceptable salts of which are listed in Berge et al., Journal of Pharmaceutical Sciences, 66:1-19 (1977), which is incorporated herein by reference in its entirety.
[0081] As used herein, "hydrate" means a compound of the present invention or a salt thereof, which further comprises a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
[0082] As used herein, "solvate" means a compound of the present invention or a salt thereof, further comprising a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and / or administrable to humans in trace amounts.
[0083]
[0084] Treatment method (dosage and administration regimen)
[0085] In the present invention, the safety of NXC736 was confirmed in a clinical trial conducted on healthy adults, and an administration method capable of effectively reducing the absolute lymphocyte count in the blood by administering NXC736 was confirmed, thereby providing an effective administration method of NXC736.
[0086] In particular, in the present invention, when an administration method capable of effectively reducing the absolute lymphocyte count in blood by administering NXC736 to a healthy animal was applied to an animal model of alopecia areata, one of the lymphocyte-mediated diseases, it was demonstrated through animal experiments that the disease could actually be effectively treated.
[0087] Absolute lymphocyte count has been used as a biomarker for the development or diagnosis of alopecia areata, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, and focal segmental glomerulosclerosis (J Clin Invest. 2007 Aug 1; 117(8): 2019-2027. doi: 10.1172 / JCI31942, Biomed Res Int. 2018; 2018: 4961753. doi: 10.1155 / 2018 / 4961753, J Clin Lab Anal. 2021 Jun; 35(6): e23774. doi: 10.1002 / jcla.23774, BMJ Case Rep. 2015; 2015: bcr2015211765. doi: 10.1136 / bcr-2015-211765), those skilled in the art use absolute lymphocyte count suppression to determine the effectiveness of treatment for a given disease.
[0088] Accordingly, the present invention provides a pharmaceutical composition for preventing or treating a lymphocyte-mediated disease, which comprises the therapeutic substance as an active ingredient, wherein the active ingredient is administered to a subject in need thereof in a dose equivalent to about 40 mg to about 80 mg of a compound represented by Chemical Formula 1 (in one embodiment, a compound represented by Chemical Formula 2).
[0089] For example, the active ingredient may be administered to an individual in need thereof in an amount of about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, about 70 mg, about 71 mg, about 72 mg, about 73 mg, about 74 mg, about A pharmaceutical composition is provided, characterized in that it is administered in a dosage equivalent to 75 mg, about 76 mg, about 77 mg, 78 mg, about 79 mg or about 80 mg.
[0090] In addition, the above-mentioned effective ingredient may be administered to an individual in need thereof in a dose equivalent to a dose within any range of about 40 mg to about 80 mg of the compound represented by Chemical Formula 1 (in one embodiment, the compound represented by Chemical Formula 2).
[0091] In one embodiment, the effective ingredient may be administered in a dose equivalent to about 50 mg to about 70 mg of the compound represented by chemical formula 1 (in one embodiment, the compound represented by chemical formula 2).
[0092] In another embodiment, the active ingredient may be administered in a dose equivalent to about 55 mg to about 65 mg of the compound represented by Chemical Formula 1 (in one embodiment, the compound represented by Chemical Formula 2).
[0093] In another embodiment, the active ingredient may be administered in a dose equivalent to about 60 mg of the compound represented by chemical formula 1 (in one embodiment, the compound represented by chemical formula 2).
[0094] In the present invention, the pharmaceutical composition may be administered once a day, twice a day, or three times a day.
[0095] In one embodiment, the pharmaceutical composition may be administered twice a day.
[0096] The above pharmaceutical composition has the advantage that the decrease in absolute lymphocyte count is maintained for a longer period of time when administered twice a day than when administered once a day.
[0097] In the present invention, the pharmaceutical composition may be administered at intervals of about 6 hours to about 24 hours.
[0098] For example, the pharmaceutical composition may be administered about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
[0099] In one embodiment, the pharmaceutical composition may be administered at intervals of about 8 hours to about 16 hours.
[0100] In another embodiment, the pharmaceutical composition may be administered at intervals of about 10 to about 14 hours.
[0101] In another embodiment, the pharmaceutical composition may be administered at intervals of about 11 to about 13 hours.
[0102] In another embodiment, the pharmaceutical composition may be administered at intervals of about 12 hours.
[0103] In the present invention, the pharmaceutical composition may be characterized in that it is administered for at least 14 days.
[0104] For example, the pharmaceutical composition may be administered for at least about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, about 28 days, about 29 days, about 30 days, about 31 days, about 32 days, about 33 days, about 34 days, about 35 days, about 36 days, about 37 days, about 38 days, about 39 days, about 40 days, about 41 days, about 42 days, about 43 days, about 44 days, about 45 days, about 46 days, about 47 days, about 48 days, about 49 days, or about 50 days or more.
[0105] In addition, the pharmaceutical composition can be used for at least about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about It may be administered for 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, or about 52 weeks or more.
[0106] Additionally, the pharmaceutical composition may be administered for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months or more.
[0107] In the present invention, the pharmaceutical composition can be administered orally or parenterally.
[0108] In one embodiment, the pharmaceutical composition may be administered orally.
[0109] In the present invention, the pharmaceutical composition may be formulated as a capsule or tablet suitable for oral administration.
[0110] In the present invention, the pharmaceutical composition may additionally include a pharmaceutically acceptable carrier.
[0111] In one embodiment, the active ingredient may be administered as an unprocessed or pure chemical substance, for example, as a powder in a capsule formulation.
[0112] In another embodiment, the active ingredient may be formulated and administered as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
[0113] Pharmaceutical compositions can be prepared by any suitable method, typically by homogeneously mixing the active compound(s) with a liquid or finely divided solid carrier, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
[0114] In pharmaceutical compositions, conventional excipients, such as binders, fillers, acceptable wetting agents, tableting lubricants, and disintegrating agents, can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations can be in the form of dry powders that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives, such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavoring and coloring agents, can be added to the liquid preparations. Parenteral dosage forms can be prepared by dissolving a compound of the present invention in a suitable liquid vehicle, sterile filtering the solution, and then filling and sealing it in a suitable vial or ampoule. These are just a few examples of the many suitable methods well known in the art for the preparation of dosage forms.
[0115] The compounds of the present invention can be formulated into pharmaceutical compositions using techniques well known to those skilled in the art. Suitable pharmaceutically acceptable carriers other than those mentioned herein are known in the art; see, for example, Remington, The Science and Practice of Pharmacy, 20th Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.).
[0116] Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (e.g., buccal and sublingual), vaginal, or parenteral (e.g., intramuscular, subcutaneous, and intravenous) administration, or for administration by inhalation, insufflation, or transdermal patch. Transdermal patches dispense the drug at a controlled rate by presenting the drug for absorption in an effective manner with minimal drug degradation. Typically, transdermal patches comprise an impermeable backing layer, a single pressure-sensitive adhesive, and a removable protective layer with a release liner. Those skilled in the art will understand and appreciate appropriate techniques for fabricating effective transdermal patches according to the needs of the artisan.
[0117] Accordingly, the compounds of the present invention may be incorporated into pharmaceutical preparations and unit dosage forms thereof together with conventional adjuvants, carriers, or diluents, and may be used in such forms as solids, such as tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, gels, or filled capsules thereof (all for oral use); in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may contain conventional ingredients in conventional proportions, with or without additional active compounds or ingredients, and such unit dosage forms may contain any suitable effective amount of the active ingredient corresponding to the intended daily dosage range for use.
[0118] For oral administration, the pharmaceutical composition may be, for example, in the form of a tablet, capsule, suspension, or liquid. The pharmaceutical composition is preferably prepared in the form of a dosage unit containing a specific amount of the active ingredient. Examples of such dosage units include capsules, tablets, powders, granules, or suspensions containing conventional additives such as lactose, mannitol, corn starch, or potato starch; binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatin; disintegrants such as corn starch, potato starch, or sodium carboxymethylcellulose; and lubricants such as talc or magnesium stearate. The active ingredient may also be administered by injection in a composition in which, for example, saline, dextrose, or water can be used as a suitable pharmaceutically acceptable carrier.
[0119] For preparing pharmaceutical compositions from the compounds of the present invention, suitable pharmaceutically acceptable carriers may be solids, liquids, or mixtures of both. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. The solid carrier may comprise one or more ingredients, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or encapsulating materials.
[0120] In powders, the carrier may be a finely divided solid present in a mixture with the finely divided active ingredient.
[0121] In the tablet, the active ingredient is mixed with a carrier having the necessary binding capacity in an appropriate ratio and compressed into a desired shape and size.
[0122] Powders and tablets may contain various percentages of the active ingredient. A typical amount in a powder or tablet may be from 0.5 to about 99 percent of the active ingredient. However, those skilled in the art will recognize that amounts outside these ranges may be required. Suitable carriers for powders and tablets include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low-melting waxes, cocoa butter, and the like. The term "formulation" is intended to include formulating the active ingredient together with an encapsulating material as a carrier, so as to provide a capsule in which the active ingredient is surrounded by and associated with the carrier, with or without the carrier. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
[0123] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injectable liquid preparations can be formulated as solutions in aqueous polyethylene glycol solutions. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions or suspensions in nontoxic parenterally acceptable diluents or solvents, for example, solutions in 1,3-butanediol.
[0124] Acceptable vehicles and solvents include water, Ringer's solution, and isotonic sodium chloride solution. Sterile fixed oils are also commonly used as a solvent or suspending medium. Any non-irritating fixed oil, including synthetic mono- or diglycerides, can be used for this purpose. Fatty acids, such as oleic acid, can also be used in the preparation of injectables.
[0125] Accordingly, the compounds according to the present invention may be formulated for parenteral administration (e.g., by injection, e.g., bolus injection or continuous infusion) and presented in unit dosage form in preservative-added ampoules, prefilled syringes, small volume injectors, or multi-dose containers. The pharmaceutical compositions may take forms such as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending agents, stabilizers, and / or dispersing agents.
[0126] Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of a sterile solid or by lyophilization from a solution, for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0127] Aqueous preparations suitable for oral use can be prepared by dissolving or suspending the above active ingredient in water and adding suitable colorants, flavors, stabilizers, and thickeners according to the purpose.
[0128] Aqueous suspensions suitable for oral use can be prepared by dispersing the finely divided active ingredient in water together with a viscous substance, such as a natural or synthetic gum, resin, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agent.
[0129] Also included are solid-form preparations intended to be converted to liquid-form preparations for oral administration immediately prior to use. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active ingredient, colorants, flavoring agents, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers, and the like.
[0130] For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments, creams or lotions or as transdermal patches.
[0131] Ointments and creams may be formulated using an aqueous or oily base, for example, with the addition of suitable thickeners and / or gelling agents. Lotions may be formulated using an aqueous or oily base, and will typically also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners, or colorants.
[0132] Formulations suitable for topical administration to the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
[0133] The solution or suspension is applied directly to the nasal cavity by conventional means, for example, by dropper, pipette or spray.
[0134] The formulation may be provided in single- or multi-dose form. In the latter case, it may be provided with a dropper, pipette, or spray to enable administration to the subject in a predetermined volume.
[0135]
[0136] According to the present invention, in a hematological test after administration of the pharmaceutical composition, the absolute lymphocyte count decrease (decrease rate) was about 32% at 40 mg and about 46% at 80 mg in a single administration (i.e., the absolute lymphocyte count after administration was about 68% and about 54%, respectively, compared to the absolute lymphocyte count before administration, resulting in a decrease to at least about 70% of the initial level), and in the repeated administrations, it was about 57% at 40 mg, about 68% at 60 mg, and about 64% at 80 mg (i.e., the absolute lymphocyte count after administration was about 43%, about 32%, and about 36%, respectively, compared to the lymphocyte count before administration, resulting in a decrease to at least about 50% of the initial level) (Fig. 9).
[0137] Therefore, in the present invention, the absolute lymphocyte count can be suppressed to about 70% or less after administration of the pharmaceutical composition compared to before administration.
[0138] For example, the pharmaceutical composition may have an absolute lymphocyte count of about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 52%, about 51%, about 50%, about 49%, about 48%, about 47%, about 46%, about 45%, about 44%, about 43%, about 42%, about 41%, about 40%, about 39%, about 38%, about 37%, about 36%, about 35%, about 34%, about It can be suppressed to 33%, about 32%, about 31%, or about 30% or less.
[0139] In another aspect, the pharmaceutical composition can suppress the absolute lymphocyte count by about 60% or less after administration compared to before administration.
[0140] In another embodiment, the pharmaceutical composition can suppress the absolute lymphocyte count by about 50% or less after administration compared to before administration.
[0141] In another embodiment, the pharmaceutical composition can suppress the absolute lymphocyte count by about 40% or less after administration compared to before administration.
[0142] In another embodiment, the pharmaceutical composition can suppress the absolute lymphocyte count by about 35% or less after administration compared to before administration.
[0143] In the present invention, the lymphocyte-mediated disease may be, but is not limited to, alopecia areata, inflammatory bowel disease, interstitial fibrosis and tubular atrophy, or focal segmental glomerulosclerosis.
[0144] In one aspect, the lymphocyte-mediated disease is alopecia areata.
[0145] In the present invention, administration of the pharmaceutical composition may mean administration of an active ingredient in the pharmaceutical composition.
[0146] In another aspect of the present invention, the active ingredient or the pharmaceutical composition may be provided in the form of a kit including instructions for instructing a method of administration (administration dose, administration cycle and / or administration period) to a subject in need of prevention or treatment of a lymphocyte-mediated disease.
[0147] In another aspect, the present invention provides an administration method comprising a step of administering the effective ingredient or the pharmaceutical composition to a subject in need thereof in a dose equivalent to 40 to 80 mg of a compound represented by Chemical Formula 1.
[0148] In the present invention, the administration method may be for the treatment of a lymphocyte-mediated disease, and therefore, the administration method may be a therapeutic method.
[0149] In another aspect, the present invention relates to the use of the above-mentioned active ingredient or the above-mentioned pharmaceutical composition in the manufacture of a drug for the treatment of a lymphocyte-mediated disease, wherein the drug is a drug for administration in a dose equivalent to 40 to 80 mg of a compound represented by Chemical Formula 1.
[0150] In the present invention, the drug may contain an effective ingredient in a dose equivalent to 40 to 80 mg of a compound represented by Chemical Formula 1.
[0151] In another aspect, the present invention relates to the use of the above-mentioned active ingredient or the above-mentioned pharmaceutical composition for the treatment of a lymphocyte-mediated disease, wherein the above-mentioned active ingredient or the above-mentioned pharmaceutical composition is administered in a dose equivalent to 40 to 80 mg of the compound represented by Chemical Formula 1.
[0152] In another aspect, the present invention relates to the use of the above-mentioned effective ingredient or the above-mentioned pharmaceutical composition for the treatment of a lymphocyte-mediated disease, wherein the above-mentioned effective ingredient or the above-mentioned pharmaceutical composition is to be administered in a dose equivalent to 40 to 80 mg of the compound represented by the chemical formula 1.
[0153] The detailed description of the above-mentioned administration method or treatment method, medicinal use, and Swiss-type medicinal use is the same as the description of the above-mentioned pharmaceutical composition, unless there is a contradiction, to avoid duplicate description.
[0154] For example, the above-described effective ingredient or pharmaceutical composition may be administered according to various dosages or usage methods (frequency, cycle, period, etc.) described as suitable for administering the effective ingredient or pharmaceutical composition as described above, and the above-described drug may be prepared so as to be administered according to various dosages or usage methods (frequency, cycle, period, etc.) described as suitable for administering the effective ingredient or pharmaceutical composition as described above.
[0155] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0156]
[0157] Example 1. Phase 1 clinical trial
[0158]
[0159] A randomized, double-blind, placebo-controlled, dose-escalation, single- and multiple-dose phase 1 clinical trial was conducted to evaluate the safety, tolerability, and pharmacokinetic / pharmacodynamic characteristics of compound 1 (NXC736) after oral administration to healthy adult males.
[0160]
[0161] 1-1. Drugs for clinical trials
[0162]
[0163] Clinical trial drug (NXC736 tablets) and its dosage
[0164] The clinical trial drug product is a white, round, film-coated tablet (1 mg, 3 mg tablet) or a yellow, round, film-coated tablet (10, 20 mg, 40 mg, 60 mg, 80 mg tablet) containing the active ingredient (main ingredient) NXC736 and excipients such as diluents, binders, disintegrants, fluidizing agents, and lubricants. The NXC736 clinical trial drug product is manufactured as an 84 mg film-coated tablet containing 1 mg and 3 mg of the main ingredient, or a 334 mg film-coated tablet containing 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg of the main ingredient, and can be stored at room temperature (1 to 30°C) in an airtight container.
[0165]
[0166] Placebo and its dosage
[0167] The placebo is manufactured as a white, circular, film-coated tablet weighing 84 mg or a yellow, circular, film-coated tablet weighing 334 mg, containing the same amount of diluent, binder, disintegrant, fluidizing agent, and lubricant as the test drug, but excluding the active ingredient NXC736. Like the test drug, it can be stored at room temperature (1 to 30°C) in an airtight container.
[0168]
[0169] 1-2. Test subjects
[0170]
[0171] In this clinical trial, a total of 42 subjects were randomly assigned to a single dose, and 39 subjects completed the study according to the protocol. A total of 33 subjects were assigned to the multiple-dose study, and 32 of them completed the study according to the protocol. The analysis groups are shown in Tables 1 and 2.
[0172]
[0173] [Table 1]
[0174] Single-dose trial subjects
[0175]
[0176]
[0177] [Table 2]
[0178] Repeated dose trial subjects
[0179]
[0180]
[0181] 1-3. Administration method
[0182]
[0183] Single dose studies: 1 mg, 3 mg, 10 mg, 20 mg, 40 mg, 80 mg
[0184] Subjects received a single oral dose of the investigational drug on an empty stomach at approximately 9:00 AM on the day of administration, after fasting for at least 10 hours. In the single-dose study, subjects were hospitalized for 8 days after administration and discharged. They were then observed through outpatient visits until day 21. Blood samples were drawn once before administration and at regular intervals after administration, followed by hematological tests.
[0185]
[0186] Repeated dose studies: 20 mg twice daily, 40 mg twice daily, 60 mg twice daily, 80 mg twice daily
[0187] Subjects fasted for at least 10 hours before the first dose. The clinical trial drug was then administered orally twice daily for 13 days, and once on the 14th day, on an empty stomach, at approximately 9:00 AM and 9:00 PM. The twice-daily regimen lasted approximately 14 days. Subjects were discharged on the 21st day after the first dose and observed through outpatient visits until the 36th day. Blood samples were drawn once before dosing and at regular intervals thereafter, followed by hematological tests.
[0188]
[0189] 1-4. Safety test results
[0190] No serious adverse reactions were observed in single-dose and repeated-dose trials. Most adverse reactions were mild and resolved during the study period.
[0191] In a single-dose trial, 23 adverse reactions occurred in 9 of the 39 subjects who received the investigational drug. Of these, 12 were adverse drug reactions (ADRs) assessed by the investigators as having a causal relationship with the investigational drug. No adverse reactions required discontinuation of dose escalation, and no serious adverse reactions occurred. Fisher's exact test confirmed that there were no significant differences in the frequency of adverse reactions between dose groups.
[0192] As expected from the drug's mechanism of action, a decrease in heart rate after administration was observed in most subjects administered NXC736, and the degree increased with increasing administration dose. However, this phenomenon was confirmed to be alleviated with repeated administration compared to single administration. In addition, most of the observed bradycardia was not clinically significant, and all cases collected as adverse reactions were asymptomatic. As a result of comprehensive evaluation of the results of physical examination, vital signs, 12-lead electrocardiogram, pulmonary function test, and ophthalmological examination, it was confirmed that the safety and tolerability were excellent for up to 14 days of administration at a dose of 80 mg twice daily.
[0193]
[0194] Adverse reactions that occurred in each dose group were organized according to SOC (System organ) and PT (preferred term).
[0195]
[0196] [Table 3]
[0197] Treatment-Emergent Adverse Events (TEAEs) by SOC and PT - Single Ascending Dose Trial (SAD)
[0198]
[0199]
[0200]
[0201] [Table 4]
[0202] Adverse drug reactions (ADRs) by SOC and PT - Single Ascending Dose Study (SAD)
[0203]
[0204]
[0205] [Table 5]
[0206] Treatment-Emergent Adverse Events (TEAEs) by SOC and PT - Multiple Ascending Dose Trials (MAD)
[0207]
[0208]
[0209]
[0210] [Table 6]
[0211] Adverse drug reactions (ADRs) by SOC and PT - Multiple Ascending Dose Study (MAD)
[0212]
[0213] 1-5. Pharmacokinetic test results
[0214] The clinical trial drug was rapidly absorbed into the body after a single dose, reaching peak plasma concentrations approximately 1 hour later. The average elimination half-life was approximately 10 hours, and virtually no excretion was observed in the urine (Figure 1).
[0215] Meanwhile, in the repeated administration test, the clinical trial drug accumulated approximately twice as much at steady state compared to the first administration (Figure 2).
[0216] After repeated administration of the clinical trial drug, dose proportionality of Cmax,ss and AUCtau,ss was confirmed (Fig. 3).
[0217]
[0218] 1-6. Pharmacodynamic test results
[0219] In both single-dose and repeat-dose studies, the absolute lymphocyte count (ALC) steadily decreased for up to 6 hours after administration, but it quickly recovered to the pre-dose level within about 1 day after single administration and within about 1 to 2 days after repeat administration. In the single-dose study, the absolute lymphocyte count decreased only by about 46% at the highest dose of 80 mg, but in the repeat-dose study, after 14 days of repeated administration, the absolute lymphocyte count decreased by up to 70% in the group receiving 60 mg twice daily or higher. In the single-dose study, the correlation between the drug and systemic exposure-pharmacodynamic parameters was relatively unclear due to the relatively long observation period compared to the actual duration of action of the drug. However, in the repeat-dose study, a clear increase in the pharmacodynamic parameters was observed when the drug was administered twice daily at doses of 20 mg to 60 mg, and a strong correlation was also observed with systemic exposure. When 80 mg was administered twice daily, the maximum absolute lymphocyte count reduction was approximately 60 to 70%, similar to that when 60 mg was administered twice daily. This confirmed that the pharmacological action was saturated at doses higher than 60 mg twice daily (Fig. 4, Fig. 5).
[0220]
[0221] Example 2. Determination of pharmaceutically effective dose
[0222]
[0223] Alopecia areata is an autoimmune disease driven by T lymphocytes. It is known that hair loss occurs when T lymphocytes attack hair follicles due to the destruction of the immune privilege surrounding the hair follicle. Therefore, suppressing these T lymphocytes is known to be a method for treating alopecia areata, and JAK inhibitors such as Baricitinib (Olumiant) and Ritlecitinib (Litfulo) have shown therapeutic effects in alopecia areata through the suppression of T lymphocytes (doi.org / 10.3389 / fimmu.2023.1243556).
[0224]
[0225] 2-1. Confirmation of the absolute lymphocyte count suppression effect following administration of NXC736 in healthy rats.
[0226] To confirm the effect on the inhibition of lymphocyte changes after oral administration (QD) of NXC736 to rats (SD rats, Coretec) at a single dose of 20 mg / kg once daily orally (BID) at a dose of 5 mg / kg or 10 mg / kg twice daily (1 additional dose 12 hours after the first dose), lymphocyte changes in peripheral blood flow were measured using an automatic hematology counter (Advia 2020i, SIEMENS) for a total of 10 times at 0, 2, 4, 8, 12, 16, 20, 24, 36, and 48 hours, with the first dose as time point 0.
[0227] When administered orally once a day at a dose of 20 mg / kg, lymphocytes were suppressed by up to 92% in 12 hours, but recovered to 60% in 24 hours, and 100% in 48 hours. On the other hand, when administered orally twice a day at a dose of 5 mg / kg, lymphocytes were suppressed by up to 78% in 4 hours after the first administration, and approximately 90% in 4 hours after the second administration (16 hours after the first administration), and recovered to approximately 50% in 24 hours, and then recovered to the pre-administration state. In addition, when a dose of 10 mg / kg was administered orally twice a day, it was confirmed that lymphocytes were suppressed by up to 83% 4 hours after the first administration, lymphocytes were suppressed by up to 94% 4 hours after the second administration (i.e., 16 hours after the first administration), and the suppression effect of about 80% was maintained for up to 24 hours and the suppression effect of about 70% was maintained for up to 36 hours (Fig. 6).
[0228] From the above results, it was confirmed that the lymphocyte suppression effect was superior even with a lower dosage when administered twice a day compared to when administered once a day.
[0229]
[0230] 2-2. Confirmation of the inhibitory effect on alopecia areata using the C3H / HeJ alopecia areata mouse model.
[0231] The efficacy of NXC736 on alopecia areata was evaluated using the C3H / HeJ mouse model (Jackson Lab, Saeron Bio). C3H / HeJ mice are experimental animals that naturally develop alopecia areata as they age. By proliferating lymph node cells obtained from C3H / HeJ mice that are naturally alopecia areata induced at least 20 weeks of age and injecting them into 10-16 week-old C3H / HeJ mice that are not alopecia areata induced, alopecia areata can be induced.
[0232] C3H / HeJ mice, 10 to 16 weeks old and not induced with alopecia areata, were divided into two groups: a control group (sterile distilled water administration group) and an NXC736 administration experimental group. Five mice were randomly assigned to each group, and lymph node cells were expanded and injected into C3H / HeJ mice. From the time of injection, NXC736 was administered orally to the NXC736 administration experimental group at 3 mg / kg or 10 mg / kg, and the same volume of sterile distilled water was administered orally to the control group twice a day at the same time for 12 weeks. The AA lesion area and disease-free ratio were measured at two-week intervals. The animal breeding room was maintained at a temperature of 23±3℃, a relative humidity of 50±10%, and a 12-hour light and dark cycle. The experimental animals were raised in isolation boxes (ThreeShine) and were provided with experimental animal feed and water ad libitum.
[0233] After 12 weeks, the area of circular hair loss lesions was photographed and quantified using the Image J program (Version 1.44p). As a result, compared to the area of circular hair loss lesions in the control group, the area of circular hair loss lesions in the NXC736-administered experimental group was found to be effectively reduced, and in particular, a concentration-dependent therapeutic effect was observed according to NXC736 administration (Fig. 7).
[0234]
[0235] 2-3. Determination of the pharmaceutically effective dose through ALC measurement
[0236] ALC was measured through hematological tests in a phase 1 clinical trial. ALC was confirmed to decrease maximally at approximately 6 hours after a single dose and to return to pre-dose levels within the same day. In a single-dose test, ALC decreased by 16% at 1 mg, 27% at 3 mg, 27% at 10 mg, 25% at 20 mg, and 32% at 40 mg. Even at the highest dose of 80 mg, the decrease was only up to a maximum of 46%.
[0237] However, in repeated administration, it was confirmed that the maximum decrease in ALC during the administration interval gradually decreased as the administration was repeated and reached the maximum within 14 days, and this was also confirmed to recover to the pre-administration level within 24 hours after discontinuation of administration. In the 14-day repeated administration test, the change in ALC was reduced only to a maximum of 30% in the 20 mg twice daily dose group, similar to the single administration, but decreased by up to 57% or more in the 40 mg twice daily dose group, and by about 60% or more and up to nearly 70% in the 60 mg and 80 mg twice daily dose groups.
[0238] In addition, although the correlation between the systemic exposure and pharmacodynamic parameters of NXC736 was relatively unclear in a single-dose test, it was confirmed in a repeated-dose test that the degree of ALC reduction increased as the dose increased when 20 mg to 60 mg were administered twice daily, and a strong correlation was also observed with the systemic exposure of NXC736 (Fig. 8).
[0239] As a result, when NXC736 was administered twice a day at a dose of 40 mg or more, it showed a maximum ALC reduction effect greater than that of a single 80 mg dose, and the maximum ALC reduction when administered twice a day at a dose of 80 mg was similar to the maximum ALC reduction when administered twice a day at a dose of 60 mg, confirming that the pharmacological action reached a plateau when administered twice a day at a dose of 60 mg or more (Fig. 9).
[0240] Therefore, the effective dosage of NXC736 was determined to be 40 mg to 80 mg, which did not show any side effects in phase 1 clinical trials, showed an ALC reduction effect of at least 50%, and restored ALC to the original concentration when administration was discontinued, and was administered twice a day.
Claims
1. A pharmaceutical composition for the prevention or treatment of lymphocyte-mediated diseases, comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, wherein the active ingredient is administered to a subject in need thereof in a dose equivalent to 40 to 80 mg of the compound represented by Chemical Formula 1: [Chemical Formula 1] Here, R 1 is hydrogen; R 2 is a hydrogen or acetyl group; X is a single bond, C2 alkylene, or C2 alkenylene; A is a five-membered heteroarylene ring containing three N atoms; B is C 2-11 is a straight or branched chain alkylene; C is a single bond or phenylene; and D is hydrogen, phenyl and C 1-6 Selected from the group consisting of alkyl.
2. A pharmaceutical composition according to claim 1, characterized in that the compound represented by Chemical Formula 1 is a compound represented by Chemical Formula 2. [Chemical Formula 2] 3. A pharmaceutical composition according to claim 1, characterized in that the effective ingredient is administered in a dosage of 50 to 70 mg.
4. A pharmaceutical composition according to claim 3, characterized in that the effective ingredient is administered in a dosage of 60 mg.
5. A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition is administered once a day or twice a day.
6. A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition is administered for at least 14 days.
7. A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition is administered orally.
8. A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition is formulated as a capsule or tablet suitable for oral administration.
9. A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
10. A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition suppresses the absolute lymphocyte count to 50% or less.
11. A pharmaceutical composition according to claim 1, wherein the lymphocyte-mediated disease is alopecia areata, inflammatory bowel disease, interstitial fibrosis and tubular atrophy or focal segmental glomerulosclerosis.
Citation Information
Patent Citations
Pharmaceutical composition for preventing or treating alopecia areata as a functional antagonist for s1PR1 and s1PR4
KR102541577B1
Pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, which acts as a functional inhibitor of S1PR1 and S1PR4
KR102541578B1
Pharmaceutical composition for the prevention or treatment of focal segmental glomerulosclerosis acting as a functional inhibitor of S1PR1 and S1PR4
KR102541579B1
Pharmaceutical composition for the prevention or treatment of IFTA, which acts as a functional inhibitor of S1PR1 and S1PR4
KR102563719B1
Novel heteroaromatic ring compound, preparation method thereof, and pharmaceutical composition for use in preventing or treating S1P receptor relating diseases containing the same as an active ingredient
KR1020170087813A
